Verona Pharma plc

NasdaqGM:VRNA Stock Report

Market Cap: US$3.8b

Verona Pharma Management

Management criteria checks 3/4

Verona Pharma's CEO is Dave Zaccardelli, appointed in Feb 2020, has a tenure of 4.83 years. total yearly compensation is $6.60M, comprised of 12.4% salary and 87.6% bonuses, including company stock and options. directly owns 1.71% of the company’s shares, worth $64.69M. The average tenure of the management team and the board of directors is 2.8 years and 5.7 years respectively.

Key information

Dave Zaccardelli

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage12.4%
CEO tenure4.8yrs
CEO ownership1.7%
Management average tenure2.8yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Verona Pharma: In COPD, There's A Corner With Their Name On It

Nov 27

Verona Pharma: A Post FDA Approval Analysis

Sep 10

Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Aug 10
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst

Jun 20

Verona Pharma: Key Inflection Point Directly Ahead

May 23

Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?

Apr 26
Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?

Verona Pharma: A Few Points From The Bull And Bear Case

Feb 15

Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Jan 26
Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data

Jan 19

Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?

Oct 12
Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?

Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?

Jun 27
Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?

Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?

Mar 10
Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?

Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?

Dec 02
Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

Sep 13

Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials

Aug 19

Verona Pharma GAAP EPS of -$0.04 beats by $0.23

Aug 09

Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster

Feb 04

Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%

Feb 02

Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19

Jan 14

Verona Pharma EPS beats by $0.15

Oct 29

CEO Compensation Analysis

How has Dave Zaccardelli's remuneration changed compared to Verona Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$154m

Jun 30 2024n/an/a

-US$125m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$7mUS$820k

-US$54m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$5mUS$525k

-US$69m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$55m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$273k

-US$56m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$18mUS$229k

-US$65m

Compensation vs Market: Dave's total compensation ($USD6.60M) is about average for companies of similar size in the US market ($USD6.66M).

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.

CEO

Dave Zaccardelli (60 yo)

4.8yrs

Tenure

US$6,597,473

Compensation

Dr. David S. Zaccardelli, also known as Dave, Pharm D., has been President, Chief Executive Officer and Executive Director of Verona Pharma plc since February 1, 2020. Dr. Zaccardelli has been Director of...

Leadership Team

NamePositionTenureCompensationOwnership
David Zaccardelli
President4.8yrsUS$6.60m1.71%
$ 64.7m
Mark Hahn
Chief Financial Officer4.8yrsUS$6.18m1.57%
$ 59.4m
Kathleen Rickard
Chief Medical Officer5.8yrsUS$1.98m0.29%
$ 10.9m
Andrew Fisher
General Counselless than a yearno datano data
Victoria Stewart
Director of Communicationsno datano datano data
Matthew Casbon
VP of Sales2.3yrsno datano data
Ostra Jewell
Senior Vice President of Human Resources2.3yrsno datano data
Tara Rheault
Chief Development Officerno datano datano data
Christopher Martin
Chief Commercial Officerno datano datano data
Caroline Diaz
Senior Vice President of Regulatory Affairs3.2yrsno datano data
Kavita Aggarwal
Senior Vice President of Medical Affairs1.9yrsno datano data
Benjamin Harber
Company Secretaryno datano datano data

2.8yrs

Average Tenure

60yo

Average Age

Experienced Management: VRNA's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Zaccardelli
President4.8yrsUS$6.60m1.71%
$ 64.7m
Mahendra Gopaldas Shah
Independent Non-Executive Director8.4yrsUS$224.83k0.011%
$ 421.8k
Martin Edwards
Independent Non-Executive Director5.7yrsUS$219.74k0.022%
$ 836.1k
Kenneth Cunningham
Independent Non-Executive Director9.3yrsUS$232.47k0.010%
$ 384.4k
David Ebsworth
Independent Non-Executive Chairman10yrsUS$330.50k0.14%
$ 5.4m
Anders Ullman
Independent Non-Executive Director9.3yrsUS$219.74k0.051%
$ 1.9m
Vikas Sinha
Independent Non-Executive Director8.3yrsUS$238.83k0.011%
$ 429.8k
Christina Ackermann
Non-Executive Director1.3yrsUS$267.91k0.0064%
$ 241.9k
Lisa Deschamps
Independent Non-Executive Director3.8yrsUS$223.56k0.011%
$ 405.9k
James Brady
Independent Non-Executive Director2.8yrsUS$226.10k0%
$ 0
Michael Austwick
Independent Non-Executive Directorless than a yearno datano data

5.7yrs

Average Tenure

62yo

Average Age

Experienced Board: VRNA's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 01:22
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verona Pharma plc is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Thomas ShraderBTIG
Edward NashCanaccord Genuity